News >

Expert Sheds Light on Prostate Cancer Screening Trial

Danielle Bucco
Published: Wednesday, Nov 08, 2017

E. David Crawford, MD
E. David Crawford, MD
The European Randomized Study of Screening for Prostate Cancer (ERSPC) and United States Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) showed varying results in mortality when investigating screening for men with prostate cancer.

, E. David Crawford, MD, a professor of radiation oncology at the University of Colorado, discusses the controversy surrounding the PLCO trial, as well as the role of prostate-specific antigen (PSA) testing for men with prostate cancer.

OncLive: Can you please provide some background of the PLCO study?

Crawford: We initiated the 2 big screening trials with Europe and the United States. There were 10 centers involved in the United States screening trial. It started out looking at screening for prostate cancer but got held up by the National Institutes of Health because there was an interest in adding other cancers to this screening trial. It took 3 years from the time we planned on starting this in prostate cancer for it to be launched as a PLCO trial in prostate, lung, colorectal, and ovarian cancer.  
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication